A$2.46 0.2 7.9%
Last Trade - 5:10am
| Market Cap | £291.6m |
| Enterprise Value | £244.1m |
| Revenue | £2.30m |
| Position in Universe | 396th / 1839 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.007 | 1.39 | 1.85 | 2.74 | 3.25 | 4.70 | 3.40 | 8.60 | +264.2% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company, which seeks to find new uses for old drugs. The Company has commenced the open labelled Phase II clinical trial, investigating the role of the drug PPS in treating traumatic Bone Marrow Lesions. The Company's Rhinosul has properties consisting of both histamine stabilizing and anti-inflammatory properties. The Company focuses on repurposing PPS under ZILOSUL name, as a treatment for bone marrow edema (BME) lesions following traumatic injury.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | May 2, 2014 |
| Public Since | August 20, 2015 |
| No. of Shareholders: | 14,881 |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 229,169,548 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | L 15 500 Collins Street, MELBOURNE, 3000, Australia |
| Web | http://paradigmbiopharma.com/ |
| Phone | +61 3 96295566 |
| Contact | () |
| Auditors | RSM Australia Partners |
As of 5:10am, shares in Paradigm Biopharmaceuticals are trading at A$2.46, giving the company a market capitalisation of £291.6m. This share price information is delayed by 15 minutes.
Shares in Paradigm Biopharmaceuticals are currently trading at A$2.46 and the price has moved by -22.18% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Paradigm Biopharmaceuticals price has moved by -28.28% over the past year.
Of the analysts with advisory recommendations for Paradigm Biopharmaceuticals, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Paradigm Biopharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Paradigm Biopharmaceuticals is scheduled to issue upcoming financial results on the following dates:
Paradigm Biopharmaceuticals does not currently pay a dividend.
Paradigm Biopharmaceuticals does not currently pay a dividend.
Paradigm Biopharmaceuticals does not currently pay a dividend.
To buy shares in Paradigm Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Paradigm Biopharmaceuticals are currently trading at A$2.46, giving the company a market capitalisation of £291.6m.
Here are the trading details for Paradigm Biopharmaceuticals:
Based on an overall assessment of its quality, value and momentum, Paradigm Biopharmaceuticals is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Paradigm Biopharmaceuticals are currently priced at A$2.46. At that level they are trading at 10.83% discount to the analyst consensus target price of 0.00.
Analysts covering Paradigm Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -0.166 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Paradigm Biopharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -25.48%. At the current price of A$2.46, shares in Paradigm Biopharmaceuticals are trading at -18.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Paradigm Biopharmaceuticals.
Paradigm Biopharmaceuticals's management team is headed by:
Here are the top five shareholders of Paradigm Biopharmaceuticals based on the size of their shareholding:
